|
|
Blood, 1 November 2006, Vol. 108, No. 9, pp. 3161-3167.
Prepublished online as a Blood First Edition Paper on July 20, 2006; DOI 10.1182/blood-2005-01-026690.
Previous Article | Next Article 
Submitted January 13, 2006
Accepted June 26, 2006
Risk of Non-Hodgkin lymphoma (NHL) in relation to germline
variation in DNA repair and related genes
Deirdre A Hill*, Sophia S Wang, James R Cerhan, Scott Davis, Wendy Cozen, Richard K Severson, Patricia Hartge, Sholom Wacholder, Meredith Yeager, Stephen J Chanock, and Nathaniel Rothman
University of New Mexico, Albuquerque, Cancer Center and Dept of Internal Medicine
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD
Mayo Clinic College of Medicine, Rochester, MN, USA and University of Iowa, Iowa City, IA, USA.
Fred Hutchinson Cancer Research Center and University of Washington, Seattle
Dept. Of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles
Karmanos Cancer Institute and Dept. of Family Medicine, Wayne State University, Detroit, MI
Core Genotyping Facility, Advanced Technology Corp, National Cancer Institute, NIH, DHHS, Gaithersbu
* Corresponding author; email: dahill{at}salud.unm.edu.
Chromosomal translocations, insertions, and deletions are
common early events in NHL carcinogenesis, and implicated
in their formation are endogenous processes involved in
antigen-receptor diversification, such as V(D)J
recombination. DNA repair genes respond to the double- and
single-strand breaks induced by these processes, and may
influence NHL etiology. We examined 34 genetic variants in
19 genes within or related to five DNA repair pathways
among 1172 cases and 982 matched controls who participated
in a population-based NHL study in Los Angeles, Seattle,
Detroit and Iowa from 1998-2000. Cases were more likely
than controls to have the RAG1 820 Arg/Arg (Odds ratio
(OR) 2.7; 95% confidence interval (CI) 1.4-5.0) than
Lys/Lys genotypes, with evidence of a gene dosage effect
(p-trend=0.0008) and less likely to have the LIG4 (DNA
Ligase IV) 9 Ile/Ile (OR 0.5; 95% CI 0.3-0.9) than
Thr/Thr genotype (p-trend =0.03) in the non-homologous end
joining (NHEJ)/V(D)J pathway. These NHEJ/V(D)J-related
gene variants represent promising candidates for further
studies of NHL etiology, and require replication in other
studies.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Articles in Blood Online:
-
RAG1 and BRCA2 polymorphisms in non-Hodgkin lymphoma
- Kathryn Scott, Peter J. Adamson, Sharon L. Barrans, Lisa J. Worrillow, Eleanor V. Willett, and James M. Allan
Blood 2007 109: 5522-5523.
[Full Text]
[PDF]
-
NHL and genomic variability in RAG1 and BRCA2
- Deirdre A. Hill, Sophia Wang, Patricia Hartge, and Nathaniel Rothman
Blood 2007 109: 5523.
[Full Text]
[PDF]
-
Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER Case-Control Study
- Unhee Lim, Sophia S. Wang, Patricia Hartge, Wendy Cozen, Linda E. Kelemen, Stephen Chanock, Scott Davis, Aaron Blair, Maryjean Schenk, Nathaniel Rothman, and Qing Lan
Blood 2007 109: 3050-3059.
[Abstract]
[Full Text]
[PDF]
|
|